Top

Published in:

01-06-2011 | Movement Disorders - Review Article

What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors: Rüdiger Hilker, Angelo Antonini, Per Odin

Published in: Journal of Neural Transmission | Issue 6/2011

Abstract

Motor complications impair quality of life and cause severe disability in patients with advanced Parkinson’s disease (PD). Since they are often refractory to medical therapy, interventional therapies have been developed, which can provide a considerable reduction of daily off-time and dopaminergic dyskinesias. Continuous dopaminergic drug delivery (CDD) is based on the steady stimulation of striatal dopamine receptors by subcutaneous apomorphine or duodenal l-DOPA infusions via portable minipumps. Advances in the understanding of basal ganglia functioning and in neurosurgical, electrophysiological and neuroimaging techniques have led to a renaissance of neurosurgery for advanced PD. Deep brain stimulation of the subthalamic nucleus (STN-DBS) is the most invasive procedure promising great benefit and the highest level of independency for suitable patients, but is definitely associated with surgical risks and DBS-related side effects. Each of these more or less invasive therapy options has its own profile, and a thorough consideration of its advantages and drawbacks for the individual situation is mandatory. In this paper, we summarize relevant facts for this decision and provide some guidelines for a responsible counseling of eligible patients.

Alegret M, Valldeoriola F, Marti M, Pilleri M, Junque C, Rumia J et al (2004) Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord 19:1463–1469PubMedCrossRef

Antonini A (2007) Continuous dopaminergic stimulation–from theory to clinical practice. Parkinsonism Relat Disord 13 Suppl:S24–S28PubMedCrossRef

Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother 9:859–867PubMedCrossRef

Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L et al (2007) Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 22:1145–1149PubMedCrossRef

Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis 5:244–246PubMedCrossRef

Arnulf I, Bejjani BP, Garma L, Bonnet AM, Houeto JL, Damier P et al (2000) Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 55:1732–1734PubMed

Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM et al (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotact Funct Neurosurg 62:76–84PubMedCrossRef

Benabid AL, Chabardes S, Mitrofanis J, Pollak P (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol 8:67–81PubMedCrossRef

Bowron A (2004) Practical considerations in the use of apomorphine injectable. Neurology 62:S32–S36PubMed

Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G et al (2002) Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59:932–934PubMed

Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245PubMedCrossRef

De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 77:450–453PubMedCrossRef

Deleu D, Hanssens Y, Northway MG (2004) Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging 21:687–709PubMedCrossRef

Derost PP, Ouchchane L, Morand D, Ulla M, Llorca PM, Barget M et al (2007) Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 68:1345–1355PubMedCrossRef

Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE et al (2006a) Deep brain stimulation: postoperative issues. Mov Disord 21(Suppl 14):S219–S237PubMedCrossRef

Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K et al (2006b) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355:896–908PubMedCrossRef

Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000PubMedCrossRef

Diamond A, Jankovic J (2005) The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry 76:1188–1193PubMedCrossRef

Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151–166PubMedCrossRef

Hagell P, Odin P (2001) Apomorphine in the treatment of Parkinson’s disease. J Neurosci Nurs 33:21–34–37–28PubMedCrossRef

Herzog J, Volkmann J, Krack P, Kopper F, Potter M, Lorenz D et al (2003) Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 18:1332–1337PubMedCrossRef

Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M et al (2004) Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson’s disease. J Cerebr Blood Flow Metab 24:7–16

Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T et al (2005) Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 76:1217–1221PubMedCrossRef

Hjort N, Ostergaard K, Dupont E (2004) Improvement of sleep quality in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 19:196–199PubMedCrossRef

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474PubMedCrossRef

Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ et al (1993) Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 8:165–170PubMedCrossRef

Kalbe E, Voges J, Weber T, Haarer M, Baudrexel S, Klein JC et al (2009) Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 72:42–49PubMedCrossRef

Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20:151–157PubMedCrossRef

Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE (2003) Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 99:489–495PubMedCrossRef

Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R et al (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21(Suppl 14):S290–S304PubMedCrossRef

Krack P, Kumar R, Ardouin C, Dowsey PL, McVicker JM, Benabid AL et al (2001) Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 16:867–875PubMedCrossRef

Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C et al (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349:1925–1934PubMedCrossRef

Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for on–off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20:262–265PubMedCrossRef

Lagrange E, Krack P, Moro E, Ardouin C, Van Blercom N, Chabardes S et al (2002) Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 59:1976–1978PubMed

Lezcano E, Gomez-Esteban JC, Zarranz JJ, Lambarri I, Madoz P, Bilbao G et al (2004) Improvement in quality of life in patients with advanced Parkinson’s disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol 11:451–454PubMedCrossRef

Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E et al (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91–95PubMedCrossRef

Lyons KE, Wilkinson SB, Overman J, Pahwa R (2004) Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 63:612–616PubMed

Macia F, Perlemoine C, Coman I, Guehl D, Burbaud P, Cuny E et al (2004) Parkinson’s disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 19:206–212PubMedCrossRef

Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17:1235–1241PubMedCrossRef

Meiler B, Andrich J, Muller T (2008) Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 23:145–146PubMedCrossRef

Menon R, Stacy M (2007) Apomorphine in the treatment of Parkinson’s disease. Expert Opin Pharmacother 8:1941–1950PubMedCrossRef

Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804PubMedCrossRef

Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F et al (2004) Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years. Arch Gerontol Geriatr Suppl (9):291–296

Neef C, van Laar T (1999) Pharmacokinetic–pharmacodynamic relationships of apomorphine in patients with Parkinson’s disease. Clin Pharmacokinet 37:257–271PubMedCrossRef

Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson’s disease—long-term experience. Acta Neurol Scand 104:343–348PubMedCrossRef

Nutt JG (2007) Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 22:1–9PubMedCrossRef

Nyholm D, Aquilonius SM (2004) Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 27:245–256PubMedCrossRef

Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C et al (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26:156–163PubMedCrossRef

Nyholm D, Jansson R, Willows T, Remahl IN (2005a) Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 65:1506–1507PubMedCrossRef

Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R et al (2005b) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216–223PubMed

Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM (2008) Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 31:63–73PubMedCrossRef

Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 5:677–687PubMedCrossRef

Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI (2006) Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta-analysis. Lancet Neurol 5:578–588PubMedCrossRef

Piallat B, Benazzouz A, Benabid AL (1996) Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8:1408–1414PubMedCrossRef

Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson’s disease: a long-term follow up. J Neurol Neurosurg Psychiatry 65:709–716PubMedCrossRef

Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44:S1–S9PubMedCrossRef

Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L (1993) Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patients. Adv Neurol 60:656–659PubMed

Quinn N, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson’s disease: response to intravenous infusion of levodopa. Lancet 2:412–415PubMedCrossRef

Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 100:163–167PubMedCrossRef

Rodriguez-Oroz MC, Zamarbide I, Guridi J, Palmero MR, Obeso JA (2004) Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 4 years after surgery: double blind and open label evaluation. J Neurol Neurosurg Psychiatry 75:1382–1385PubMedCrossRef

Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S et al (2005) Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 128:2240–2249PubMedCrossRef

Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE (2000) Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson’s disease. Brain 123(Pt 10):2091–2108PubMedCrossRef

Samanta J, Hauser RA (2007) Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin Pharmacother 8:657–664PubMedCrossRef

Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 56:251–253PubMed

Shoulson I, Glaubiger GA, Chase TN (1975) On–off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144–1148PubMed

Stacy M (2004) Apomorphine: North American clinical experience. Neurology 62:S18–S21PubMed

Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on–off oscillations. Lancet 1:403–406PubMedCrossRef

Stocchi F, Bramante L, Monge A, Viselli F, Baronti F, Stefano E et al (1993) Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 60:653–655PubMed

Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol Sci 22:93–94PubMedCrossRef

The Deep Brain Stimulations for Parkinson’s Disease Study Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 345:956–963CrossRef

Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow-up. Neurology 58:396–401PubMed

Voges J, Waerzeggers Y, Maarouf M, Lehrke R, Koulousakis A, Lenartz D et al (2006) Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery—experiences from a single centre. J Neurol Neurosurg Psychiatry 77:868–872PubMedCrossRef

Voges J, Hilker R, Botzel K, Kiening KL, Kloss M, Kupsch A et al (2007) Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 22:1486–1489PubMedCrossRef

Voges J, Kiening K, Krauss JK, Nikkhah G, Vesper J (2009) Neurosurgical standards in deep brain stimulation: consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt 80:666–672PubMedCrossRef

Volkmann J (2007) Deep brain stimulation for Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl 3):S462–S465PubMedCrossRef

Voon V, Moro E, Saint-Cyr JA, Lozano AM, Lang AE (2005) Psychiatric symptoms following surgery for Parkinson’s disease with an emphasis on subthalamic stimulation. Adv Neurol 96:130–147PubMed

Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M et al (2008) A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 131:2720–2728PubMedCrossRef

Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J et al (2007) Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130:2129–2145PubMedCrossRef

Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W (1999) Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson’s disease. Adv Neurol 80:545–548PubMed

Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO et al (2008) Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 7:605–614PubMedCrossRef

Title: What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?
Authors: Rüdiger Hilker
Angelo Antonini
Per Odin
Publication date: 01-06-2011
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 6/2011
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-010-0555-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Identification of Parkinson’s disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson’s disease patients

Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm

Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T)

Fluoxetine treatment induces EAAT2 expression in rat brain

Regulation of the immediate-early genes arc and zif268 in a mouse operant model of cocaine seeking reinstatement

Editorial comments: treatment of motor fluctuations in Parkinson’s disease